1. Academic Validation
  2. Carbonyl reductase 1 catalyzes 20β-reduction of glucocorticoids, modulating receptor activation and metabolic complications of obesity

Carbonyl reductase 1 catalyzes 20β-reduction of glucocorticoids, modulating receptor activation and metabolic complications of obesity

  • Sci Rep. 2017 Sep 6;7(1):10633. doi: 10.1038/s41598-017-10410-1.
Ruth A Morgan 1 2 Katharina R Beck 3 Mark Nixon 4 Natalie Z M Homer 5 Andrew A Crawford 4 6 Diana Melchers 7 René Houtman 7 Onno C Meijer 8 Andreas Stomby 9 Anna J Anderson 4 Rita Upreti 4 Roland H Stimson 4 Tommy Olsson 9 Tom Michoel 10 Ariella Cohain 11 Arno Ruusalepp 12 13 14 Eric E Schadt 11 Johan L M Björkegren 11 12 13 14 15 Ruth Andrew 4 5 Christopher J Kenyon 4 Patrick W F Hadoke 4 Alex Odermatt 3 John A Keen 16 Brian R Walker 4 5
Affiliations

Affiliations

  • 1 University/BHF Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK. ruth.morgan@ed.ac.uk.
  • 2 Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK. ruth.morgan@ed.ac.uk.
  • 3 Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
  • 4 University/BHF Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
  • 5 Mass Spectrometry Core Laboratory, Wellcome Trust Clinical Research Facility, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
  • 6 School of Social and Community Medicine, University of Bristol, Bristol, UK.
  • 7 PamGene International, Den Bosch, The Netherlands.
  • 8 Department of Internal Medicine, Division Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.
  • 9 Department of Public Health and Clinical Medicine, Umeå University, 901 87, Umeå, Sweden.
  • 10 The Roslin Institute, University of Edinburgh, Easter Bush Campus, Edinburgh, UK.
  • 11 Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, USA.
  • 12 Department of Physiology, Institute of Biomedicine and Translation Medicine, University of Tartu, Tartu, Estonia.
  • 13 Clinical Gene Networks AB, Stockholm, Sweden.
  • 14 Department of Cardiac Surgery, Tartu University Hospital, Tartu, Estonia.
  • 15 Integrated Cardio Metabolic Centre, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
  • 16 Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK.
Abstract

Carbonyl Reductase 1 (CBR1) is a ubiquitously expressed cytosolic Enzyme important in exogenous drug metabolism but the physiological function of which is unknown. Here, we describe a role for CBR1 in metabolism of glucocorticoids. CBR1 catalyzes the NADPH- dependent production of 20β-dihydrocortisol (20β-DHF) from cortisol. CBR1 provides the major route of cortisol metabolism in horses and is up-regulated in adipose tissue in obesity in horses, humans and mice. We demonstrate that 20β-DHF is a weak endogenous agonist of the human Glucocorticoid Receptor (GR). Pharmacological inhibition of CBR1 in diet-induced obesity in mice results in more marked glucose intolerance with evidence for enhanced hepatic GR signaling. These findings suggest that CBR1 generating 20β-dihydrocortisol is a novel pathway modulating GR activation and providing enzymatic protection against excessive GR activation in obesity.

Figures